# Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

> **NCT02189837** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 89 (actual)

## Conditions studied

- Primary Hyperlipidemia and Mixed Dyslipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Atorvastatin
- **DRUG:** Placebo to Evolocumab
- **DRUG:** Placebo to Atorvastatin

## Key facts

- **NCT ID:** NCT02189837
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-08
- **Primary completion:** 2015-02-13
- **Final completion:** 2015-03-05
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189837, "Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02189837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*